We are live on ! Find out more
ELV icon

Elevance Health

998 hedge funds and large institutions have $59.9B invested in Elevance Health in 2018 Q4 according to their latest regulatory filings, with 150 funds opening new positions, 288 increasing their positions, 403 reducing their positions, and 87 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more call options, than puts

Call options by funds: $627M | Put options by funds: $254M

72% more first-time investments, than exits

New positions opened: 150 | Existing positions closed: 87

19% more funds holding in top 10

Funds holding in top 10: 4250 (+8)

5% more funds holding

Funds holding: 946998 (+52)

0.92% more ownership

Funds ownership: 87.63%88.55% (+0.92%)

4% less capital invested

Capital invested by funds: $62.4B → $59.9B (-$2.53B)

29% less repeat investments, than reductions

Existing positions increased: 288 | Existing positions reduced: 403

Holders
998
Holders Change
+52
Holders Change %
+5.5%
% of All Funds
22.23%
Holding in Top 10
50
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+19.05%
% of All Funds
1.11%
New
150
Increased
288
Reduced
403
Closed
87
Calls
$627M
Puts
$254M
Net Calls
+$373M
Net Calls Change
+$191M
Name Holding Trade Value Shares
Change
Change in
Stake
N
301
Nuveen
North Carolina
$7.83M -$13M -47,148 -61%
NGM
302
North Growth Management
British Columbia, Canada
$7.83M
BNP Paribas Asset Management
303
BNP Paribas Asset Management
France
$7.75M +$428K +1,558 +5%
PAIM
304
Punch & Associates Investment Management
Minnesota
$7.72M -$74.5K -271 -0.9%
KWILP
305
Kiwi Wealth Investments Limited Partnership
New Zealand
$7.72M +$8.08M +29,392 New
Commonwealth Equity Services
306
Commonwealth Equity Services
Massachusetts
$7.45M +$575K +2,091 +8%
Renaissance Technologies
307
Renaissance Technologies
New York
$7.3M +$7.64M +27,800 New
FCM
308
Flinton Capital Management
Pennsylvania
$7.2M -$2.82M -10,268 -27%
FNBT
309
FineMark National Bank & Trust
Florida
$7.15M +$305K +1,108 +4%
HH
310
HWG Holdings
Texas
$7.11M +$5.7M +20,721 +326%
B
311
BP
United Kingdom
$7.09M -$1.51M -5,500 -17%
SAM
312
Securian Asset Management
Minnesota
$6.88M -$112K -409 -2%
EAM
313
Eagle Asset Management
Florida
$6.87M +$3.8M +13,826 +112%
ACM
314
Atika Capital Management
New York
$6.7M +$137K +500 +2%
SFS
315
Strategic Financial Services
New York
$6.63M +$9.62K +35 +0.1%
BOTW
316
Bank of the West
California
$6.51M -$269K -980 -4%
MWNA
317
Marshall Wace North America
New York
$6.12M -$405K -1,474 -6%
SG Americas Securities
318
SG Americas Securities
New York
$6.11M -$9.34M -33,963 -59%
ASA
319
Armstrong Shaw Associates
Connecticut
$6.08M -$192K -700 -3%
CA
320
Cornerstone Advisors
North Carolina
$6.04M
PIA
321
Piedmont Investment Advisors
North Carolina
$6.01M +$2.07M +7,513 +49%
MA
322
Montag & Associates
Georgia
$5.93M +$713K +2,593 +13%
AIM
323
Achmea Investment Management
Netherlands
$5.93M -$6.84M -24,858 -52%
TAM
324
Tyers Asset Management
Texas
$5.93M -$2.33M -8,456 -27%
SGH
325
Sivik Global Healthcare
Connecticut
$5.91M -$1.37M -5,000 -18%

ELV Hedge Fund Activity: Q4 2018 in Review

998 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Elevance Health (ELV) for Q4 2018, worth a combined $59.9B — down 4.1% from $62.4B a quarter earlier.

Buyers outnumbered sellers: 150 funds opened new ELV positions and 87 closed out — a net gain of 63 holders — while 288 added to existing stakes and 403 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $419M. The largest seller was Two Sigma Advisers, cutting an estimated $231M.

  • 998 institutional investors held Elevance Health (ELV) as of Q4 2018, up from 946 in Q3 2018.
  • Funds reported $59.9B of Elevance Health stock for Q4 2018, down 4.1% quarter-over-quarter.
  • 150 funds opened new Elevance Health positions in Q4 2018 and 87 closed out, a net change of +63 holders.
  • The largest Elevance Health buyer in Q4 2018 was JP Morgan Chase, an estimated $419M added.
  • The largest Elevance Health seller in Q4 2018 was Two Sigma Advisers, an estimated $231M sold.

Based on aggregated 13F filings for Q4 2018.